![Juha Aimo Koivurinta](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Juha Aimo Koivurinta is currently the Chief Executive Officer & Director at FibroGen Europe Oy since 2000.
He previously worked as a Director at AGC Biologics A.
Actieve functies van Juha Aimo Koivurinta
Bedrijven | Functie | Begin |
---|---|---|
Fibrogen Europe Oy
![]() Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | Algemeen Directeur | 01-04-2000 |
Eerdere bekende functies van Juha Aimo Koivurinta
Bedrijven | Functie | Einde |
---|---|---|
AGC Biologics A/S
![]() AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
AGC Biologics A/S
![]() AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
Fibrogen Europe Oy
![]() Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | Health Technology |